EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling

Lu Chen, Ruyu Han, Shujie Zhai, Yimeng Wang, Xiaochen Ma, Zhizhuo Cao, Guangtao Li, Shaojun Zhang, Wenchen Gong, Jihui Hao, Tianqiang Song

Drug Resistance Updates · 2026-09 · 88 · 101440

DOI: 10.1016/j.drup.2026.101440 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Lu Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Researc…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Microenvironment, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy. METHODS: This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy enrolled patients with resectable, early-stage HCC. All patients received tislelizumab monotherapy; non-responders received subsequent lenvatinib combination therapy preoperatively. RESULTS: For the overall efficacy of all 36 patients, the objective response rates were 13.9% and 30.6% as per the Response Evaluation Criteria in Solid Tumours v1.1 and modified Response Evaluation Criteria in Solid Tumours, respectively. Among the 33 patients who underwent resection, the major pathological response rate was 33.3% and the pathological complete response rate was 15.2%. Overall, grade ≥ 3 treatment-emergent adverse events occurred in 11.1%, with no surgical delays. Monotherapy responses were predicted by pretreatment tumour microenvironment features. Immune-regulatory cancer-associated fibroblasts colocalized with T cells identified responders, whereas angiogenic-metabolic signatures predicted resistance. A multimodal model integrating blood-based and imaging biomarkers accurately identified monotherapy-sensitive patients (average precision, 0.9167). The specificity for identifying responders was 100%. CONCLUSIONS: These preliminary findings suggest that neoadjuvant immunotherapy monotherapy exhibits promising antitumour activity and demonstrates a manageable safety profile in early-stage HCC. The tailored stratification approach appears clinically feasible and may help minimize unnecessary exposure to combination therapy-related toxicity while retaining tentative therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor MicroenvironmentAntibodies, Monoclonal, HumanizedHumansFemaleMaleNeoadjuvant TherapyMiddle AgedAgedProspective StudiesNeoplasm StagingPathologic Complete ResponseImmunotherapyTreatment OutcomeAdult

Stichwörter der Autor:innen

Hepatocellular carcinomaMultimodal prediction modelNeoadjuvant immunotherapySpatial transcriptomicsTislelizumab

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianj…
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
  • Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China. Electronic address: szhang5@outlook.com.
  • Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. Electronic address: gongwenchen@tmu.edu.cn.
  • Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, Tianj…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, L., Han, R., Zhai, S., Wang, Y., Ma, X., Cao, Z., Li, G., Zhang, S., Gong, W., Hao, J., & Song, T. (2026). Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling. Drug Resistance Updates, 88, 101440. https://doi.org/10.1016/j.drup.2026.101440

Vancouver

Chen L, Han R, Zhai S, Wang Y, Ma X, Cao Z, et al. Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling. Drug Resistance Updates. 2026;88:101440. doi:10.1016/j.drup.2026.101440

BibTeX
@article{Chen2026,
  author = {Chen, Lu and Han, Ruyu and Zhai, Shujie and Wang, Yimeng and Ma, Xiaochen and Cao, Zhizhuo and Li, Guangtao and Zhang, Shaojun and Gong, Wenchen and Hao, Jihui and Song, Tianqiang},
  title = {Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {88},
  pages = {101440},
  doi = {10.1016/j.drup.2026.101440}
}
Kostenlos starten →